Biosimilars Industry Buoyed By EMA Paper On Reducing Clinical Trials

Paper On Streamlining Development Wins Plaudits At MfE Conference

 
• By Dave Wallace
  
Biosimilars are heading for a more streamlined path to market in Europe (Shutterstock)

More from Medicines for Europe

More from Policy & Regulation